DK1330452T3 - Pyrazinderivater som modulatorer af tyrosinkinaser - Google Patents

Pyrazinderivater som modulatorer af tyrosinkinaser

Info

Publication number
DK1330452T3
DK1330452T3 DK01975243T DK01975243T DK1330452T3 DK 1330452 T3 DK1330452 T3 DK 1330452T3 DK 01975243 T DK01975243 T DK 01975243T DK 01975243 T DK01975243 T DK 01975243T DK 1330452 T3 DK1330452 T3 DK 1330452T3
Authority
DK
Denmark
Prior art keywords
modulators
tyrosine kinases
pyrazine derivatives
pyrazine
derivatives
Prior art date
Application number
DK01975243T
Other languages
Danish (da)
English (en)
Inventor
Gee Hong Kuo
Peter Connolly
Catherine Prouty
Alan Deangelis
Aihua Wang
Linda Jolliffe
Steve Middleton
Stuart Emanuel
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22879359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1330452(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Application granted granted Critical
Publication of DK1330452T3 publication Critical patent/DK1330452T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01975243T 2000-09-20 2001-09-19 Pyrazinderivater som modulatorer af tyrosinkinaser DK1330452T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23396800P 2000-09-20 2000-09-20
PCT/US2001/029175 WO2002024681A2 (en) 2000-09-20 2001-09-19 Pyrazine derivatives as modulators of tyrosine kinases

Publications (1)

Publication Number Publication Date
DK1330452T3 true DK1330452T3 (da) 2009-03-16

Family

ID=22879359

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01975243T DK1330452T3 (da) 2000-09-20 2001-09-19 Pyrazinderivater som modulatorer af tyrosinkinaser

Country Status (14)

Country Link
US (1) US6710048B2 (de)
EP (1) EP1330452B1 (de)
JP (1) JP2004523474A (de)
AR (1) AR035494A1 (de)
AT (1) ATE415396T1 (de)
AU (1) AU9458401A (de)
CA (1) CA2423050A1 (de)
DE (1) DE60136731D1 (de)
DK (1) DK1330452T3 (de)
ES (1) ES2315308T3 (de)
HK (1) HK1054393B (de)
PT (1) PT1330452E (de)
TW (1) TWI254711B (de)
WO (1) WO2002024681A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (de) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Kondensierte heterozyklische Succinimid-Verbindungen und Analoga daraus, Modulatoren der nuklearen Hormonrezeptorfunktion
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7087636B2 (en) * 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1501514B1 (de) * 2002-05-03 2012-12-19 Exelixis, Inc. Proteinkinasemodulatoren und verfahren zur derer anwendung
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
AUPS251402A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Kinase inhibitors
AU2003249369A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
GB0215775D0 (en) * 2002-07-06 2002-08-14 Astex Technology Ltd Pharmaceutical compounds
CA2501719C (en) * 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
US8030336B2 (en) * 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
US20040121968A1 (en) * 2002-12-23 2004-06-24 Alexander Ljubimov Antiangiogenesis by inhibiting protein kinase CK2 activity
DK1603570T5 (da) * 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005003101A2 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
EP1670794A2 (de) 2003-09-30 2006-06-21 Amgen Inc. Vanilloidrezeptorliganden und deren verwendung bei behandlungen
AU2004295050A1 (en) * 2003-11-24 2005-06-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
ATE481134T1 (de) 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
WO2006051311A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
GB0500226D0 (en) * 2005-01-07 2005-02-16 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
EP1917244A2 (de) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
US8466154B2 (en) 2006-10-27 2013-06-18 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
CN101687839A (zh) * 2007-05-16 2010-03-31 拜尔农科股份有限公司 杀真菌剂苯基-嘧啶基-氨基衍生物
EP2203436A1 (de) * 2007-09-17 2010-07-07 Neurosearch A/S Pyrazinderivate und ihre verwendung als kaliumkanalmodulatoren
KR100898037B1 (ko) * 2007-10-05 2009-06-01 한국화학연구원 금속촉매의 커플링반응에 의한 트리알킬피라진 유도체의제조방법
WO2010000353A1 (en) 2008-06-09 2010-01-07 Sanofi-Aventis Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
NZ713361A (en) * 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
IN2012DN01273A (de) * 2009-09-04 2015-05-15 Novartis Ag
US20110185353A1 (en) * 2010-01-27 2011-07-28 Jack Matthew Mitigating Problems Arising From Incompatible Software
CN103298787A (zh) * 2010-11-17 2013-09-11 诺瓦提斯公司 3-(氨基芳基)-吡啶化合物
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
CA2840883C (en) * 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
NZ746607A (en) 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
WO2015076800A1 (en) * 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
JP6607870B2 (ja) 2014-05-13 2019-11-20 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ７０モジュレーターならびにその作製および使用方法
CN110799190B (zh) 2017-03-27 2024-04-19 卡都瑞恩医药有限公司 杂环化合物
GB201715414D0 (en) * 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
GB201715318D0 (en) 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
EP3836932A2 (de) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Verfahren zur behandlung von bauchspeicheldrüsenkrebs
JP7447098B2 (ja) 2018-09-25 2024-03-11 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド アミノピリミジン化合物
EP4182308B1 (de) 2020-07-15 2024-09-04 Chiesi Farmaceutici S.p.A. Pyridazinylaminoderivate als alk5-inhibitoren
JP7824282B2 (ja) 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用
US20250011299A1 (en) 2021-09-21 2025-01-09 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
AU2023207775A1 (en) 2022-01-11 2024-08-22 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514400A (en) * 1981-10-26 1985-04-30 William H. Rorer, Inc. Cardiotonic 5-heteroaryl-pyridone
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
EP0994875B1 (de) 1997-06-30 2004-03-10 Targacept, Inc. 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
ATE252572T1 (de) * 1998-06-30 2003-11-15 Lilly Co Eli 5-ht1f agonisten
CN1374953A (zh) * 1999-09-16 2002-10-16 田边制药株式会社 含氮的6－员芳香环化合物
PL365238A1 (en) 2000-02-16 2004-12-27 Neurogen Corporation Substituted arylpyrazines

Also Published As

Publication number Publication date
JP2004523474A (ja) 2004-08-05
US6710048B2 (en) 2004-03-23
TWI254711B (en) 2006-05-11
HK1054393B (en) 2009-08-28
WO2002024681A2 (en) 2002-03-28
CA2423050A1 (en) 2002-03-28
ES2315308T3 (es) 2009-04-01
EP1330452B1 (de) 2008-11-26
AU9458401A (en) 2002-04-02
DE60136731D1 (de) 2009-01-08
US20030060629A1 (en) 2003-03-27
WO2002024681A3 (en) 2002-06-20
ATE415396T1 (de) 2008-12-15
HK1054393A1 (en) 2003-11-28
AR035494A1 (es) 2004-06-02
PT1330452E (pt) 2009-01-22
EP1330452A2 (de) 2003-07-30

Similar Documents

Publication Publication Date Title
DK1330452T3 (da) Pyrazinderivater som modulatorer af tyrosinkinaser
DK1117659T3 (da) Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
DK1463506T3 (da) Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser
DK1490064T3 (da) Substituerede pyridinoner som modulatorer af p38 MAP kinase
DK1276738T3 (da) 2-amino-3- (alkyl) - pyrimidinderivater som GSK3-betainhibitorer
DK1317442T3 (da) Quinolinonderivater som tyrosinkinaseinhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20035766L (no) Aminonikotinatderivater som glukokinase (GLK) modulatorer
DK1284974T3 (da) Triazolyltropanderivater som CCR5-modulatorer
IS6524A (is) 5-alkýlpyrídó(3-3-D)pyrimídín týrósín kínasa tálmar
NO20011574L (no) Substituerte 3-cyanokinoliner som proteintyrosin-kinsase- inhibitorer
DK1686999T3 (da) Pyrazolderivater som inhibitorer af receptortyrosinkinaser
NO20021239L (no) Pteridinoner som kinase-inhibitorer
DK1532138T3 (da) Inhibitorer af tyrosinkinaser
DK1047694T3 (da) Bicykliske heteroaromatiske forbindelser som proteintyrosinkinaseinhibitorer
ATE372988T1 (de) Pyrimidin-derivate
DZ3223A1 (fr) Inhibiteurs de tyrosine kinases
DK1667991T3 (da) Quinazolinderivater som tyrosinkinaseinhibitorer
AR028596A1 (es) Nuevos derivados de fenilglicina
NO20035728D0 (no) Pyrrolopyrimidiner som proteinkinaseinhibitorer
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
DK1276721T3 (da) Methylering af indolforbindelser under anvendelse af dimethylcarbonat
NO20035206D0 (no) Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
DK1016404T3 (da) Vandigt præparat af beta-caroten